Cidara Therapeutics, Inc. (CDTX): Jeffrey Stein , CEO of Cidara Therapeutics, Inc. purchased 4,310 shares on May 20, 2016. The Insider buying transaction was reported by the company on May 23, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.51 per share for a total value of $49,608.10 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 27, 2015, Jeffrey Stein (CEO) purchased 6,700 shares at $15.28 per share price.On Nov 23, 2015, Kevin Forrest (CFO) purchased 7,087 shares at $14.23 per share price.Also, On Apr 22, 2015, Nina S Kjellson (director) purchased 200,000 shares at $16.00 per share price.On Apr 22, 2015, Patrick J Heron (director) purchased 200,000 shares at $16.00 per share price.
Cidara Therapeutics Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Cidara Therapeutics Inc which led to swings in the share price. The shares opened for trading at $11.12 and hit $11.79 on the upside , eventually ending the session at $11.49, with a gain of 3.14% or 0.35 points. The heightened volatility saw the trading volume jump to 3,36,260 shares. The 52-week high of the share price is $18.07 and the company has a market cap of $159,194 M . The 52-week low of the share price is at $9.48.
Cidara Therapeutics Inc. formerly K2 Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery development and commercialization of anti-infective products. The Company’s products are the formulations of its compound CD101 which is an echinocandin. Its products include CD101 intravenous (biafungin) and CD101 topical (topifungin). In addition it owns an immunotherapy technology platform Cloudbreak. The Company is also developing other candidates for the treatment of bacterial and viral infections. CD101 IV and CD101 topical are in early stage of preclinical development. The Company’s Cloudbreak development candidates includeC001 and C016. It has conducted preclinical studies to evaluate the tolerability toxicity and pharmacokinetic profile of C001 in mice and guinea pigs. Cloudbreak development candidates have demonstrated preclinical proof-of-principle efficacy and safety in preclinical studies.